USP28 and TP53BP1 are also significantly enriched in genome-wide screenings for resistance to anti-cancer drugs (in 6 or 9 out of the 10 anticancer drug screens, for TP53BP1 or USP28, respectively (Segal et al. 2023)). Here, TP53BP1 is linked to cancer.